LLY - Eli Lilly and Company

NYSE - NYSE Delayed Price. Currency in USD
85.82
-0.39 (-0.45%)
At close: 4:02PM EST
Stock chart is not supported by your current browser
Previous Close86.21
Open86.04
Bid84.71 x 100
Ask87.44 x 100
Day's Range85.27 - 86.14
52 Week Range74.00 - 89.09
Volume4,445,813
Avg. Volume3,236,082
Market Cap89.87B
Beta0.12
PE Ratio (TTM)40.85
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & Yield2.25 (2.61%)
Ex-Dividend Date2018-02-14
1y Target EstN/A
Trade prices are not sourced from all markets
  • Merck’s & Co.’s Valuation in January 2018
    Market Realist15 hours ago

    Merck’s & Co.’s Valuation in January 2018

    Who’s Watching Merck & Co. in January 2018?Merck & Co.’s valuation

  • Reuters2 days ago

    U.S. Senate committee advances Azar nomination as health secretary

    A U.S. Senate committee on Wednesday voted to move forward the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar's nomination, with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.

  • Reuters2 days ago

    Key U.S. Senate committee advances Azar nomination for HHS secretary

    A key Senate committee on Wednesday voted to advance the nomination of Alex Azar, a former drug industry executive and lobbyist whom President Donald Trump has tapped to be the next secretary of Health and Human Services. The Senate Finance Committee voted 15-12 to advance Azar's nomination with all but one Democrat opposing. To receive final confirmation Azar will have to receive a majority vote in the 100-seat Senate, which Republicans control with 51 seats.

  • TheStreet.com2 days ago

    A Rally in Eli Lilly Could Heal Traders, Investors

    Prices have improved the past eight weeks and now I want to turn up the volume.

  • Is Eli Lilly and Company a Buy in 2018?
    Motley Fool2 days ago

    Is Eli Lilly and Company a Buy in 2018?

    The outlook is complicated for this big pharma stock.

  • Teva Pharmaceutical: Still Focused on New Product Launches
    Market Realist2 days ago

    Teva Pharmaceutical: Still Focused on New Product Launches

    Can Teva Pharmaceutical's Restructuring Plan Help It Recuperate? The Vanguard Total International Stock ETF (VXUS) holds 0.09% of its total portfolio in TEVA stock. Teva Pharmaceutical Industries (TEVA) has its biggest value chain in the market as the company’s core strength, which has helped it establish itself as the leading generics pharmaceutical company in the world.

  • How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines
    Investor's Business Daily3 days ago

    How This Biotech Stock Could Top Bigger Rivals In Preventing Migraines

    Alder could successfully compete with larger rivals Amgen, Lilly and Teva in preventing chronic migraines, analysts said Tuesday.

  • Benzinga3 days ago

    Eli Lilly's Risks Could Be Underappreciated, Goldman Sachs Says In Downgrade

    The case for buying shares of Eli Lilly and Co (NYSE: LLY ) no longer applies, as an analysis of the company's franchise suggests investors are underappreciating the risk surrounding its biggest diabetes ...

  • Barrons.com3 days ago

    Big Pharma: Merck Zooms, Eli Lilly Lags

    Big pharmaceutical stocks are moving in disparate directions on Tuesday, with Merck (MRK) rising on good news while Eli Lilly (LLY) was falling after a downgrade. Merck is higher after late-stage trial data showed that Keytruda, when used with two chemotherapy drugs, was successful as a first-line treatment for lung cancer. While the blockbuster drug is already approved for use for cancer treatment, including lung cancer, the results were good news, as Merck and other Big Pharma companies are racing to bring new lung-cancer treatment options to market.  As for Eli Lilly, Goldman Sachs' Jami Rubin and her team downgraded the stock from Buy to Neutral, writing that while they are still bullish on the company's long term, they're concerned that the bull thesis is well understood and already reflected in the stock's valuation. Moreover, Rubin argues, the risk to Lilly's diabetes franchise, particularly Trulicity--the company's biggest and fastest growth driver--isn't fully appreciated by the market, and that could cause downside to consensus estimates.

  • GuruFocus.com7 days ago

    Three Diabetes Clinical Trials to Watch in 2018

    Outcomes on these three clinical trials in diabetes this year could change the way the disease is treated going into the next decade.

  • Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod
    Zacks7 days ago

    Lilly's Elanco/Aratana's Veterinary Medicine Gets EU Nod

    Eli Lilly (LLY) animal health unit Elanco and partner Aratana announce the EU approval of Galliprant for treatment of pain associated with osteoarthritis in dogs.

  • Wall Street Recommendations for Mylan in January 2018
    Market Realist7 days ago

    Wall Street Recommendations for Mylan in January 2018

    Who’s Watching Mylan in January 2018?

  • How Mylan’s Rest of the World Segment Performed in 3Q17
    Market Realist8 days ago

    How Mylan’s Rest of the World Segment Performed in 3Q17

    Who’s Watching Mylan in January 2018?

  • Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know
    Motley Fool9 days ago

    Eli Lilly & Co. at J.P. Morgan: 5 Things Investors Will Want to Know

    What's Lilly's next stage of growth? CEO Dave Ricks answered this question and more at the J.P. Morgan Healthcare Conference.

  • Ignyta’s Drug Pipeline
    Market Realist10 days ago

    Ignyta’s Drug Pipeline

    Ignyta and Its Drug Candidates for 2018

  • Reuters10 days ago

    Health secretary nominee indicates support for Medicaid overhaul

    Alex Azar, a former drug industry executive and lobbyist nominated to run the U.S. Department of Health and Human Services, indicated on Tuesday he supported a Republican bid to overhaul Medicaid and again vowed to tackle high drug prices. Azar appeared before the Senate Finance Committee on Tuesday, which will ultimately decide whether to move his nomination forward. Azar also vowed to uphold Obamacare as long as it remained the law but said that the program needed changes.

  • Trump health pick wary of government drug price negotiations
    Associated Press10 days ago

    Trump health pick wary of government drug price negotiations

    WASHINGTON (AP) — Empowering Medicare to negotiate drug prices could leave patients with reduced access to medications, President Donald Trump's pick for health secretary warned Tuesday.

  • How Was Incyte’s Revenue Stream in 3Q17?
    Market Realist10 days ago

    How Was Incyte’s Revenue Stream in 3Q17?

    As we discussed earlier, Incyte (INCY) reported revenue of $381.5 million in 3Q17, a 41.6% rise over its revenue of $269.5 million in 3Q16. This revenue growth was driven by increased demand for the drug Jakafi. The above graph shows a revenue breakup for Incyte over the last few quarters.

  • Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications
    Market Realist10 days ago

    Why AbbVie Is Focused on Expanding Risankizumab’s Label for Multiple Immunology Indications

    AbbVie (ABBV) is focused on expanding Risankizumab’s label for multiple indications such as psoriatic arthritis, ulcerative colitis, and Crohn’s disease. The company expects to witness a significant rise in demand for Crohn’s disease and ulcerative colitis patients, mainly driven by increasing diagnosis rates and the greater prevalence of patients already treated with biologics.

  • Examining Incyte’s Quarterly Revenue Trend
    Market Realist10 days ago

    Examining Incyte’s Quarterly Revenue Trend

    New Insights for Incyte Corporation as of January

  • The Wall Street Journal10 days ago

    Despite Setbacks, Drugmakers Have Plans to Fight Alzheimer’s

    Efforts to find treatments for Alzheimer’s disease suffered blows in recent days, but many companies, scientists and investors are still optimistic that they can find a way to treat the memory-robbing ...

  • Eli Lilly CEO Says Tax Reform May Lead to More Successful Deals
    Bloomberg11 days ago

    Eli Lilly CEO Says Tax Reform May Lead to More Successful Deals

    Eli Lilly & Co. Chief Executive Officer Dave Ricks said on Monday that the recent changes in U.S. tax policy will help the drugmaker lower its global tax burden as he continues to look for deals in areas ...

  • Eli Lilly CEO on Drug Pricing and Diabetes Treatment
    Bloomberg Video10 days ago

    Eli Lilly CEO on Drug Pricing and Diabetes Treatment

    Jan.09 -- David Ricks, chairman and chief executive officer at Eli Lilly & Co., discusses pricing pressures, the drug Trulicity, and the company's commitment to diabetes research. He speaks with Erik Schatzker on "Bloomberg Markets" from the JPMorgan Health Care conference in San Francisco.

  • Eli Lilly CEO Says Drug Pricing Innovation Is Needed
    Bloomberg Video10 days ago

    Eli Lilly CEO Says Drug Pricing Innovation Is Needed

    Jan.09 -- David Ricks, chairman and chief executive officer at Eli Lilly & Co., discusses drug pricing and shifting industry dynamics. He speaks with Erik Schatzker on "Bloomberg Markets" from the JPMorgan Healthcare Conference in San Francisco.